Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

RATIONALE: Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable HCC, but there are few reports on the failure of the combination treatment. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Shigeki, Kawaoka, Tomokazu, Johira, Yusuke, Miura, Ryoichi, Kosaka, Masanari, Shirane, Yuki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Yamaoka, Kenji, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ohno, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Mori, Keiichi, Arihiro, Kouji, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Aikata, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542139/
https://www.ncbi.nlm.nih.gov/pubmed/34678902
http://dx.doi.org/10.1097/MD.0000000000027576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542139/
https://www.ncbi.nlm.nih.gov/pubmed/34678902
http://dx.doi.org/10.1097/MD.0000000000027576

Ejemplares similares